We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Haemonetics (HAE) Set to Launch VASCADE MVP XL in US
Read MoreHide Full Article
Haemonetics Corporation (HAE - Free Report) recently announced the full market release of its VASCADE MVP XL — a mid-bore venous closure system. The VASCADE MVP XL system will now be available to U.S. hospitals as the newest addition to the company’s VASCADE portfolio of vascular closure systems.
With the full market release underway and an ongoing clinical trial program, the company is well-positioned to broaden the indications for the VASCADE MVP XL system to even larger access points. The latest development is expected to help Haemonetics grab opportunities in the growing vascular closure solutions space.
About VASCADE MVP XL System
The VASCADE MVP XL system provides a robust closure solution for procedures requiring 10-12F sheaths (up to 15F in outer diameter) by utilizing 58% more collagen and a larger disc than the VASCADE MVP system. The system provides closure solutions for procedures, such as cryoablation or Pulsed Field Ablation (PFA) and Left Atrial Appendage Closure (LAAC).
VASCADE MVP XL was available in a limited market release as of June 2024. Since then, the system has been used by approximately 80 physicians at more than 30 hospitals across multiple types of procedures.
More on the News
After the positive feedback during the limited market release, Haemonetics is optimistic about the availability of VASCADE MVP XL to physicians at all U.S. hospitals as soon as possible.
The VASCADE MVP XL system will complement the company’s Interventional Technologies portfolio.
Haemonetics' current VASCADE portfolio also includes the VASCADE system, designed for small-bore femoral arterial and venous closure with standard 5-6/7F procedural sheaths, and the VASCADE MVP system, designed for mid-bore multi-access femoral venous closure with 6-12F ID procedural sheaths.
Industry Prospects
Per a Precedence Research report, the global vascular closure devices market size was valued at $1.75 billion in 2023and is predicted to reach $3.30 billion by 2033, at a CAGR of 6.55% during the period. The potential rise in demand can be attributed to increasing rates of cardiovascular diseases, a surge in operations involving catheterization and a growing need for less invasive treatments.
Image Source: Zacks Investment Research
Hence, Haemonatics’ expansion to the VASCADE portfolio of vascular closure systems is well-timed.
Other Recent Developments
In July 2024, Haemonetics received CE Mark certification and the first commercial European procedures for SavvyWire — a pre-shaped pressure guidewire. The SavvyWire guidewire comes with a sensor-guided 3-in-1 solution for Transcatheter Aortic Valve Implantation (TAVI). The certification for the SavvyWire guidewire is a key step in the company’s strategy for international expansion.
In April 2024, Haemonatics received 510(k) clearance from the FDA for the TEG 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge. HAE’s cartridge-based TEG 6s system provides clinicians with complete information about a patient's coagulation profile, accelerating patient care.
Earlier in April, Haemonetics completed the acquisition of privately-held Chicago-based Attune Medical, which is the manufacturer of the ensoETM proactive esophageal cooling device. This acquisition is expected to increase Haemonetics’ revenues by $35 million.
Price Performance
Year to date, shares of HAE have lost 13.5% against the industry’s 5.8% growth.
Zacks Rank and Other Key Picks
Haemonetics currently carries a Zacks Rank #2 (Buy).
Intuitive Surgical’s shares have surged 65.6% in the past year. Estimates for the company’s earnings have moved north 5.1% to $1.65 per share for 2024 in the past 30 days.
ISRG’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.
Estimates for TransMedics’ 2024 EPS have moved up 83.3% to 22 cents in the past 30 days. Shares of the company have soared 160.4% in the past year compared with the industry’s 5.5% growth.
TMDX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.
Estimates for Quest Diagnostics’ 2024 EPS have decreased 0.4% to $2.28 in the past 30 days. In the past year, shares of DGX have risen 169.7% compared with the industry’s 10.7% growth.
In the last reported quarter, DGX delivered an earnings surprise of 1.73%. The company has a trailing four-quarter average earnings surprise of 3.31%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Haemonetics (HAE) Set to Launch VASCADE MVP XL in US
Haemonetics Corporation (HAE - Free Report) recently announced the full market release of its VASCADE MVP XL — a mid-bore venous closure system. The VASCADE MVP XL system will now be available to U.S. hospitals as the newest addition to the company’s VASCADE portfolio of vascular closure systems.
With the full market release underway and an ongoing clinical trial program, the company is well-positioned to broaden the indications for the VASCADE MVP XL system to even larger access points. The latest development is expected to help Haemonetics grab opportunities in the growing vascular closure solutions space.
About VASCADE MVP XL System
The VASCADE MVP XL system provides a robust closure solution for procedures requiring 10-12F sheaths (up to 15F in outer diameter) by utilizing 58% more collagen and a larger disc than the VASCADE MVP system. The system provides closure solutions for procedures, such as cryoablation or Pulsed Field Ablation (PFA) and Left Atrial Appendage Closure (LAAC).
VASCADE MVP XL was available in a limited market release as of June 2024. Since then, the system has been used by approximately 80 physicians at more than 30 hospitals across multiple types of procedures.
More on the News
After the positive feedback during the limited market release, Haemonetics is optimistic about the availability of VASCADE MVP XL to physicians at all U.S. hospitals as soon as possible.
The VASCADE MVP XL system will complement the company’s Interventional Technologies portfolio.
Haemonetics' current VASCADE portfolio also includes the VASCADE system, designed for small-bore femoral arterial and venous closure with standard 5-6/7F procedural sheaths, and the VASCADE MVP system, designed for mid-bore multi-access femoral venous closure with 6-12F ID procedural sheaths.
Industry Prospects
Per a Precedence Research report, the global vascular closure devices market size was valued at $1.75 billion in 2023and is predicted to reach $3.30 billion by 2033, at a CAGR of 6.55% during the period. The potential rise in demand can be attributed to increasing rates of cardiovascular diseases, a surge in operations involving catheterization and a growing need for less invasive treatments.
Image Source: Zacks Investment Research
Hence, Haemonatics’ expansion to the VASCADE portfolio of vascular closure systems is well-timed.
Other Recent Developments
In July 2024, Haemonetics received CE Mark certification and the first commercial European procedures for SavvyWire — a pre-shaped pressure guidewire. The SavvyWire guidewire comes with a sensor-guided 3-in-1 solution for Transcatheter Aortic Valve Implantation (TAVI). The certification for the SavvyWire guidewire is a key step in the company’s strategy for international expansion.
In April 2024, Haemonatics received 510(k) clearance from the FDA for the TEG 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge. HAE’s cartridge-based TEG 6s system provides clinicians with complete information about a patient's coagulation profile, accelerating patient care.
Earlier in April, Haemonetics completed the acquisition of privately-held Chicago-based Attune Medical, which is the manufacturer of the ensoETM proactive esophageal cooling device. This acquisition is expected to increase Haemonetics’ revenues by $35 million.
Price Performance
Year to date, shares of HAE have lost 13.5% against the industry’s 5.8% growth.
Zacks Rank and Other Key Picks
Haemonetics currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are Intuitive Surgical (ISRG - Free Report) , TransMedics Group (TMDX - Free Report) and Quest Diagnostics (DGX - Free Report) . While Intuitive Surgical and TransMedics sport a Zacks Rank #1 (Strong Buy) each, Quest Diagnostics carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical’s shares have surged 65.6% in the past year. Estimates for the company’s earnings have moved north 5.1% to $1.65 per share for 2024 in the past 30 days.
ISRG’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.
Estimates for TransMedics’ 2024 EPS have moved up 83.3% to 22 cents in the past 30 days. Shares of the company have soared 160.4% in the past year compared with the industry’s 5.5% growth.
TMDX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.
Estimates for Quest Diagnostics’ 2024 EPS have decreased 0.4% to $2.28 in the past 30 days. In the past year, shares of DGX have risen 169.7% compared with the industry’s 10.7% growth.
In the last reported quarter, DGX delivered an earnings surprise of 1.73%. The company has a trailing four-quarter average earnings surprise of 3.31%.